143 related articles for article (PubMed ID: 361132)
41. BCG in the treatment of human cancer.
Terry WD
CA Cancer J Clin; 1975; 25(4):198-203. PubMed ID: 805639
[No Abstract] [Full Text] [Related]
42. The role of immunotherapy in the management of patients with malignant melanoma.
Goodnight JE; Morton DL
World J Surg; 1979 Jul; 3(3):309-20. PubMed ID: 382645
[No Abstract] [Full Text] [Related]
43. Immunotherapy of melanoma.
Nathanson L
J Cutan Pathol; 1979 Jun; 6(3):213-26. PubMed ID: 383755
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapy and chemoimmunotherapy of malignant disease with BCG and nonviable mycobacterial fractions.
Schwarz MA; Gutterman JU; Hersh EM; Richman SP; Mavligit GM
World J Surg; 1977 Sep; 1(5):555-83. PubMed ID: 272083
[No Abstract] [Full Text] [Related]
45. Malignant melanoma.
Lichtenfeld JL
Med Clin North Am; 1977 Sep; 61(5):1013-25. PubMed ID: 330971
[No Abstract] [Full Text] [Related]
46. Intralesional BCG in the treatment of metastatic malignant melanoma.
Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
[TBL] [Abstract][Full Text] [Related]
47. Introduction to tumor immunotherapy.
Helm F; Helm J
Int J Dermatol; 1979 Apr; 18(3):205-10. PubMed ID: 457312
[No Abstract] [Full Text] [Related]
48. Adjuvant immunotherapy of malignant melanoma.
Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
[TBL] [Abstract][Full Text] [Related]
49. Monitoring of immunologic status of patients receiving BCG therapy for malignant disease.
Gross NJ; Eddie-Quartey AC
Cancer; 1976 May; 37(5):2183-93. PubMed ID: 769946
[TBL] [Abstract][Full Text] [Related]
50. A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.
Laucius JF; Bodurtha AJ; Mastrangelo JM; Bellet RE
Cancer; 1977 Nov; 40(5):2091-3. PubMed ID: 336181
[TBL] [Abstract][Full Text] [Related]
51. Combined modality therapy of malignant melanoma.
Hersh EM; Gutterman JU; McBride CM
World J Surg; 1979 Jul; 3(3):329-43. PubMed ID: 382647
[No Abstract] [Full Text] [Related]
52. Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
Gutterman JU; Richman SP; McBride CM; Burgess MA; Bartold SL; Kennedy A; Gehan EA; Mavligit G; Hersh EM
Recent Results Cancer Res; 1978; 68():359-62. PubMed ID: 752870
[No Abstract] [Full Text] [Related]
53. Multiple primary melanoma.
Moseley HS; Giuliano AE; Storm FK; Clark WH; Robinson DS; Morton DL
Cancer; 1979 Mar; 43(3):939-44. PubMed ID: 427733
[TBL] [Abstract][Full Text] [Related]
54. Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
Schmitt E; Meuret G; Waldermann F; Hagedorn M
Arch Dermatol Res; 1979 May; 264(3):319-26. PubMed ID: 464648
[TBL] [Abstract][Full Text] [Related]
55. Adoptive transfer and specific active immunization of patients with malignant melanoma.
Seigler H; Buckley CE; Sheppard LB; Horne BJ; Shingleton WW
Ann N Y Acad Sci; 1976; 277(00):522-32. PubMed ID: 1069561
[No Abstract] [Full Text] [Related]
56. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
Veronesi U; Beretta G
Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
[No Abstract] [Full Text] [Related]
57. Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
Embleton MJ; Ransom JH; McIllmurray MB; Reeves WG
Br J Cancer; 1978 Apr; 37(4):497-504. PubMed ID: 565645
[TBL] [Abstract][Full Text] [Related]
58. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
Hedley DW; McElwain TJ; Currie GA
Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
[TBL] [Abstract][Full Text] [Related]
59. Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial.
Klein WR; Bras GE; Misdorp W; Steerenberg PA; de Jong WH; Tiesjema RH; Kersjes AW; Ruitenberg EJ
Cancer Immunol Immunother; 1986; 21(2):133-40. PubMed ID: 3633215
[TBL] [Abstract][Full Text] [Related]
60. Risks of BCG intralesional therapy: an experience with melanoma.
Robinson JC
J Surg Oncol; 1977; 9(6):587-93. PubMed ID: 145518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
